Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

$Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma$

Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma

by Pourdehnad, Michael , Maciag, Paulo , Pawlyn, Charlotte , Karanes, Chatchada , Amatangelo, Michael , Pierce, Daniel W. , Arnao, Mario , Trudel, Suzanne , Casas-Avilés, Ignacio , Katz, Jessica , Martinez-Lopez, Joaquín , Popat, Rakesh , Rodríguez Otero, Paula , Gong, Jing , Ramasamy, Karthik , Mateos, María-Victoria , Vangsted, Annette J. , Lonial, Sagar , Li, Shaoyi , Orlowski, Robert Z. , Wong, Lilly , Richardson, Paul G. , Poon, Jennifer , Oriol, Albert , Spirli, Alessia , Berdeja, Jesus G. , Peluso, Teresa , Kim, Kihyun , Quach, Hang , Lamba, Manisha , Bahlis, Nizar J.

in Administration, Oral / Adverse events / Antibodies / Antineoplastic Agents - administration & dosage / Antineoplastic Agents - adverse effects / Antineoplastic Agents - therapeutic use / Biomarkers / Bone marrow / Confidence intervals / Dexamethasone / Dexamethasone - administration & dosage / Dexamethasone - adverse effects / Dexamethasone - therapeutic use / Drug dosages / Hematology / Humans / Hypotheses / Immunotherapy / Lenalidomide - adverse effects / Leukemia / Lymphocytes B / Lymphoma / Medical prognosis / Multiple myeloma / Multiple Myeloma - drug therapy / Neutropenia / Neutropenia - chemically induced / Neutrophils / Oncology / Pharmacodynamics / Pharmacokinetics / Recurrence / Schedules / Targeted cancer therapy / Treatments in Oncology / Ubiquitin-protein ligase / Ubiquitin-Protein Ligases

2023

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma

2023

Confirm

Do you wish to request the book?

$Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma$

Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma

2023

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

$Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma$

Journal Article

Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma

Pourdehnad, Michael,

Maciag, Paulo,

Pawlyn, Charlotte,

Karanes, Chatchada,

Amatangelo, Michael,

Pierce, Daniel W.,

Arnao, Mario,

Trudel, Suzanne,

Casas-Avilés, Ignacio,

Katz, Jessica,

Martinez-Lopez, Joaquín,

Popat, Rakesh,

Rodríguez Otero, Paula,

Gong, Jing,

Ramasamy, Karthik,

Mateos, María-Victoria,

Vangsted, Annette J.,

Lonial, Sagar,

Li, Shaoyi,

Orlowski, Robert Z.,

Wong, Lilly,

Richardson, Paul G.,

Poon, Jennifer,

Oriol, Albert,

Spirli, Alessia,

Berdeja, Jesus G.,

Peluso, Teresa,

Kim, Kihyun,

Quach, Hang,

Lamba, Manisha,

Bahlis, Nizar J.

2023

Overview

Oral mezigdomide is a cereblon-modifying agent that results in degradation of transcription factors essential for myeloma cell survival. Given with dexamethasone, it induced responses in 40% of heavily pretreated patients.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Administration, Oral

/ Adverse events

/ Antibodies

/ Antineoplastic Agents - administration & dosage

/ Antineoplastic Agents - adverse effects

/ Antineoplastic Agents - therapeutic use

/ Biomarkers